Adaptive Biotechnologies (ADPT) Depreciation & Amortization (CF) (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $3.4 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 21.0% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.1 million (down 11.0% YoY) and the FY2025 annual result came in at $16.0 million, down 8.26% from the prior year.
• Depreciation & Amortization (CF) declined to $3.4 million in Q1 2026 per ADPT's latest filing, from $3.7 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $5.3 million in Q3 2023, with the low at $3.4 million in Q1 2026.
• Average Depreciation & Amortization (CF) over 5 years is $4.5 million, with a median of $4.6 million recorded in 2022.
• Year-over-year, Depreciation & Amortization (CF) jumped 105.91% in 2022 and slipped 22.1% in 2024.
• Adaptive Biotechnologies' Depreciation & Amortization (CF) stood at $4.9 million in 2022, then increased by 2.18% to $5.0 million in 2023, then dropped by 20.79% to $3.9 million in 2024, then declined by 7.1% to $3.7 million in 2025, then retreated by 7.28% to $3.4 million in 2026.
• Business Quant data shows ADPT's Depreciation & Amortization (CF) at $3.4 million in Q1 2026, $3.7 million in Q4 2025, and $4.0 million in Q3 2025.